Prior to the availability of the pulmonary arterial hypertension (PAH)-specific therapy, PAH was a dreadful disease with a very poor prognosis. Better understanding of the complex pathobiology of PAH has led to a major therapeutic evolution. International regulatory agencies have approved many specific drugs with different pharmacologic pathways and routes of administration. In the year 2013, two new drugs with great potentials in managing PAH have been added to the treatment options, macitentan and riociguat. Additional drugs are expected to come in the near future. A substantial body of evidence has confirmed the effectiveness of pulmonary arterial hypertension (PAH)-specific therapies in improving the patients′ symptomatic status and sl...
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by remodelling of small...
The 1-, 3-, and 5-year survival rates of the patients included in the National Institute of Health R...
Pulmonary arterial hypertension (PAH) is a disease charac-terized by progressive remodeling of the d...
Treatment of pulmonary hypertension (PH) patients is challenging and should only be initiated after ...
The Saudi Association for Pulmonary Hypertension (previously called Saudi Advisory Group for Pulmona...
Portopulmonary hypertension (POPH) is defined as pulmonary arterial hypertension (PAH) complicated b...
Pulmonary hypertension (PH) due to left heart disease is the most common cause of pulmonary hyperten...
Pulmonary arterial hypertension (PAH) is characterized by a progressive rise in pulmonary vascular r...
Aims: The purpose of this study is to present our center′s experience in managing patients with pulm...
Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the...
There is scant published data about pulmonary hypertension (PH) from the developing countries. True ...
Pulmonary hypertension (PH) in the Intensive Care Unit (ICU) may be due to preexisting pulmonary vas...
Current international guidelines on the treatment of pulmonary arterial hypertension (PAH) are compi...
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability o...
Pulmonary arterial hypertension (PAH) is a rare and severe clinical condition characterized by lumin...
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by remodelling of small...
The 1-, 3-, and 5-year survival rates of the patients included in the National Institute of Health R...
Pulmonary arterial hypertension (PAH) is a disease charac-terized by progressive remodeling of the d...
Treatment of pulmonary hypertension (PH) patients is challenging and should only be initiated after ...
The Saudi Association for Pulmonary Hypertension (previously called Saudi Advisory Group for Pulmona...
Portopulmonary hypertension (POPH) is defined as pulmonary arterial hypertension (PAH) complicated b...
Pulmonary hypertension (PH) due to left heart disease is the most common cause of pulmonary hyperten...
Pulmonary arterial hypertension (PAH) is characterized by a progressive rise in pulmonary vascular r...
Aims: The purpose of this study is to present our center′s experience in managing patients with pulm...
Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the...
There is scant published data about pulmonary hypertension (PH) from the developing countries. True ...
Pulmonary hypertension (PH) in the Intensive Care Unit (ICU) may be due to preexisting pulmonary vas...
Current international guidelines on the treatment of pulmonary arterial hypertension (PAH) are compi...
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability o...
Pulmonary arterial hypertension (PAH) is a rare and severe clinical condition characterized by lumin...
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by remodelling of small...
The 1-, 3-, and 5-year survival rates of the patients included in the National Institute of Health R...
Pulmonary arterial hypertension (PAH) is a disease charac-terized by progressive remodeling of the d...